Differential Contributions of Serotonin Receptors to the Behavioral Effects of Indoleamine Hallucinogens in Mice

Overview

Journal J Psychopharmacol

Publisher Sage Publications

Specialty Pharmacology

Date 2010 Dec 15

PMID 21148021

Citations 76

Authors

Adam L Halberstadt

Liselore Koedood

Susan B Powell

Mark A Geyer

Affiliations

Soon will be listed here.

Abstract

Psilocin (4-hydroxy-N,N-dimethyltryptamine) is a hallucinogen that acts as an agonist at 5-HT(1A), 5-HT(2A), and 5-HT(2C) receptors. Psilocin is the active metabolite of psilocybin, a hallucinogen that is currently being investigated clinically as a potential therapeutic agent. In the present investigation, we used a combination of genetic and pharmacological approaches to identify the serotonin (5-HT) receptor subtypes responsible for mediating the effects of psilocin on head twitch response (HTR) and the behavioral pattern monitor (BPM) in C57BL/6J mice. We also compared the effects of psilocin with those of the putative 5-HT(2C) receptor-selective agonist 1-methylpsilocin and the hallucinogen and non-selective serotonin receptor agonist 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT). Psilocin, 1-methylpsilocin, and 5-MeO-DMT induced the HTR, effects that were absent in mice lacking the 5-HT(2A) receptor gene. When tested in the BPM, psilocin decreased locomotor activity, holepoking, and time spent in the center of the chamber, effects that were blocked by the selective 5-HT(1A) antagonist WAY-100635 but were not altered by the selective 5-HT(2C) antagonist SB 242,084 or by 5-HT(2A) receptor gene deletion. 5-MeO-DMT produced similar effects when tested in the BPM, and the action of 5-MeO-DMT was significantly attenuated by WAY-100635. Psilocin and 5-MeO-DMT also decreased the linearity of locomotor paths, effects that were mediated by 5-HT(2C) and 5-HT(1A) receptors, respectively. In contrast to psilocin and 5-MeO-DMT, 1-methylpsilocin (0.6-9.6 mg/kg) was completely inactive in the BPM. These findings confirm that psilocin acts as an agonist at 5-HT(1A), 5-HT(2A), and 5-HT(2C) receptors in mice, whereas the behavioral effects of 1-methylpsilocin indicate that this compound is acting at 5-HT(2A) sites but is inactive at the 5-HT(1A) receptor. The fact that 1-methylpsilocin displays greater pharmacological selectivity than psilocin indicates that 1-methylpsilocin represents a potentially useful alternative to psilocybin for development as a potential therapeutic agent.

Citing Articles

Serotonergic Psychedelics Rapidly Modulate Evoked Glutamate Release in Cultured Cortical Neurons.

Petruskova A, Guhathakurta D, Akdas E, Perello-Amoros B, Frischknecht R, Weiss E J Neurochem. 2025; 169(3):e70020.

PMID: 40022486 PMC: 11871419. DOI: 10.1111/jnc.70020.

Single-nucleus transcriptomics reveals time-dependent and cell-type-specific effects of psilocybin on gene expression.

Liao C, OFarrell E, Qalieh Y, Savalia N, Girgenti M, Kwan K bioRxiv. 2025; .

PMID: 39803502 PMC: 11722411. DOI: 10.1101/2025.01.04.631335.

Effects of psychedelics on neurogenesis and broader neuroplasticity: a systematic review.

Lima da Cruz R, Leao R, Moulin T Mol Med. 2024; 30(1):244.

PMID: 39701927 PMC: 11657683. DOI: 10.1186/s10020-024-01013-4.

Assessing the effects of 5-HT and 5-HT receptor antagonists on DOI-induced head-twitch response in male rats using marker-less deep learning algorithms.

Cyrano E, Popik P Pharmacol Rep. 2024; 77(1):135-144.

PMID: 39602080 PMC: 11743402. DOI: 10.1007/s43440-024-00679-1.

Substrate recognition by the 4-hydroxytryptamine kinase PsiK in psilocybin biosynthesis.

Rogge K, Wagner T, Hoffmeister D, Rupp B, Werten S FEBS Lett. 2024; 599(3):447-455.

PMID: 39449146 PMC: 11808438. DOI: 10.1002/1873-3468.15042.

References

Carter O, Burr D, Pettigrew J, Wallis G, Hasler F, Vollenweider F . Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors. J Cogn Neurosci. 2005; 17(10):1497-508. DOI: 10.1162/089892905774597191. View

Berendsen H, Jenck F, Broekkamp C . Selective activation of 5HT1A receptors induces lower lip retraction in the rat. Pharmacol Biochem Behav. 1989; 33(4):821-7. DOI: 10.1016/0091-3057(89)90477-2. View

Winter J, Rice K, Amorosi D, Rabin R . Psilocybin-induced stimulus control in the rat. Pharmacol Biochem Behav. 2007; 87(4):472-80. PMC: 2000343. DOI: 10.1016/j.pbb.2007.06.003. View

Gonzalez-Maeso J, Weisstaub N, Zhou M, Chan P, Ivic L, Ang R . Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron. 2007; 53(3):439-52. DOI: 10.1016/j.neuron.2007.01.008. View

Geyer M, Russo P, Masten V . Multivariate assessment of locomotor behavior: pharmacological and behavioral analyses. Pharmacol Biochem Behav. 1986; 25(1):277-88. DOI: 10.1016/0091-3057(86)90266-2. View

Fantegrossi W, Reissig C, Katz E, Yarosh H, Rice K, Winter J . Hallucinogen-like effects of N,N-dipropyltryptamine (DPT): possible mediation by serotonin 5-HT1A and 5-HT2A receptors in rodents. Pharmacol Biochem Behav. 2007; 88(3):358-65. PMC: 2322878. DOI: 10.1016/j.pbb.2007.09.007. View

Carter O, Pettigrew J, Burr D, Alais D, Hasler F, Vollenweider F . Psilocybin impairs high-level but not low-level motion perception. Neuroreport. 2004; 15(12):1947-51. DOI: 10.1097/00001756-200408260-00023. View

Strassman R . Human psychopharmacology of N,N-dimethyltryptamine. Behav Brain Res. 1996; 73(1-2):121-4. DOI: 10.1016/0166-4328(96)00081-2. View

Blair J, Cumbay M, Watts V, Barker E, Nichols D . Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. J Med Chem. 2000; 43(24):4701-10. DOI: 10.1021/jm000339w. View

10.

Yamamoto T, Ueki S . Behavioral effects of 2,5-dimethoxy-4-methylamphetamine (DOM) in rats and mice. Eur J Pharmacol. 1975; 32(02):156-62. DOI: 10.1016/0014-2999(75)90278-2. View

11.

Gouzoulis-Mayfrank E, Heekeren K, Thelen B, Lindenblatt H, Kovar K, Sass H . Effects of the hallucinogen psilocybin on habituation and prepulse inhibition of the startle reflex in humans. Behav Pharmacol. 1998; 9(7):561-6. DOI: 10.1097/00008877-199811000-00011. View

12.

Adams L, Geyer M . Effects of DOM and DMT in a proposed animal model of hallucinogenic activity. Prog Neuropsychopharmacol Biol Psychiatry. 1985; 9(2):121-32. DOI: 10.1016/0278-5846(85)90074-0. View

13.

Pierce P, Peroutka S . Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex. Psychopharmacology (Berl). 1989; 97(1):118-22. DOI: 10.1007/BF00443425. View

14.

Spencer Jr D, Glaser T, Traber J . Serotonin receptor subtype mediation of the interoceptive discriminative stimuli induced by 5-methoxy-N,N-dimethyltryptamine. Psychopharmacology (Berl). 1987; 93(2):158-66. DOI: 10.1007/BF00179927. View

15.

Umbricht D, Vollenweider F, Schmid L, Grubel C, Skrabo A, Huber T . Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia. Neuropsychopharmacology. 2002; 28(1):170-81. DOI: 10.1038/sj.npp.1300005. View

16.

Sard H, Kumaran G, Morency C, Roth B, Toth B, He P . SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005; 15(20):4555-9. DOI: 10.1016/j.bmcl.2005.06.104. View

17.

Darmani N, Martin B, Pandey U, Glennon R . Do functional relationships exist between 5-HT1A and 5-HT2 receptors?. Pharmacol Biochem Behav. 1990; 36(4):901-6. DOI: 10.1016/0091-3057(90)90098-3. View

18.

Geyer M, Light R, Rose G, Petersen L, Horwitt D, Adams L . A characteristic effect of hallucinogens on investigatory responding in rats. Psychopharmacology (Berl). 1979; 65(1):35-40. DOI: 10.1007/BF00491975. View

19.

Sanchez C, Arnt J, Moltzen E . Assessment of relative efficacies of 5-HT1A receptor ligands by means of in vivo animal models. Eur J Pharmacol. 1996; 315(3):245-54. DOI: 10.1016/s0014-2999(96)00621-8. View

20.

Vickers S, Easton N, Malcolm C, Allen N, Porter R, Bickerdike M . Modulation of 5-HT(2A) receptor-mediated head-twitch behaviour in the rat by 5-HT(2C) receptor agonists. Pharmacol Biochem Behav. 2001; 69(3-4):643-52. DOI: 10.1016/s0091-3057(01)00552-4. View